Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Huangqi is a Traditional Chinese Medicine (TCM) compound formulation developed by the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine specifically for the treatment of myasthenia gravis (MG). The formulation is primarily composed of *Astragalus membranaceus* (Huangqi) as the chief ingredient, which is known for its immunomodulatory and 'Qi-tonifying' properties. It is often combined with other herbs such as *Cimicifuga foetida* and *Bupleurum chinense* to address the underlying pathology of MG according to TCM principles. Mechanistically, Fufang Huangqi acts as an immunomodulator by regulating the balance of T-cell subsets (including Th1/Th2 and Th17/Treg populations) and reducing the production of pathogenic anti-acetylcholine receptor (AChR) antibodies. It is typically used as an adjunctive therapy to conventional treatments like cholinesterase inhibitors and corticosteroids to improve clinical symptoms, increase muscle strength, and reduce relapse rates in patients with MG.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang huangqi.